TRIGEN
LIVE

Serial Number

98674089

Owner

Trigen Laboratories, LLC

Attorney

NEIL C. JONES

First Use Date

Oct 25, 2013

Filing Date

Jul 30, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TRIGEN Trademark

Serial Number: 98674089

TRIGEN is a trademark filed by Trigen Laboratories, LLC on July 30, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Trigen Laboratories, LLC (2 trademarks)

1880 McFarland Parkway, Suite 110
Alpharetta, GA 30005

Entity Type: 16

Trademark Details

Filing Date

July 30, 2024

Registration Date

Not Registered

First Use Anywhere

October 25, 2013

First Use in Commerce

October 25, 2013

Published for Opposition

December 9, 2025

Goods & Services

Pharmaceutical products development; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development; Pharmaceutical company services, namely, professional medical company services being pharmaceutical product research and development; Generic pharmaceutical research and development

Full line of pharmaceutical products, namely pharmaceutical products and preparations for treating diseases and conditions in gynecology and women's health, pharmaceutical products and preparations for use as prenatal supplements, pharmaceutical products and preparations for use as iron supplements, pharmaceutical products and preparations for use as multivitamin and mineral supplements, vitamin supplements and nutraceuticals for use as dietary supplements, pharmaceutical products and preparations for treating symptoms associated with menopause, pharmaceutical products and preparations for treating menopause and post menopause symptoms and conditions, pharmaceutical products and preparations for use in pain management, pharmaceutical products and preparations for use as opioid analgesics, pharmaceutical products and preparations for treating musculoskeletal conditions, and pharmaceutical products and preparations for use as a centrally-acting agents for musculoskeletal conditions; pharmaceutical preparations for managing and relieving pain and inflammation, pharmaceutical preparations for use in the treatment of musculoskeletal conditions, soft tissue conditions, and arthritis, pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, and executive functioning disorder, and pharmaceutical products and preparations for use as antidepressants

Filing History

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Apr 8, 2026 ETOP
OPPOSITION INSTITUTED NO. 999999
Apr 8, 2026 OP.I
ASSIGNED TO EXAMINER
Apr 6, 2026 DOCK
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 7, 2026 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 9, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 9, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 3, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 13, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 10, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 10, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 29, 2025 GNFN
FINAL REFUSAL E-MAILED
Aug 29, 2025 GNFR
FINAL REFUSAL WRITTEN
Aug 29, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 6, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 6, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 6, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 6, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 23, 2025 NWOS
NEW APPLICATION ENTERED
Jul 30, 2024 NWAP